Dr. McDermott on Immunotherapy as a Standard of Care in RCC
David F. McDermott, MD
David F. McDermott, MD, director of the Biologic Therapy Program at Beth Israel Deaconess Medical Center, discusses immunotherapy as a standard of care for patients with renal cell carcinoma (RCC).
According to McDermott, immunotherapy will be the standard of care for patients with RCC in 2018; however, it will not benefit everyone.
Patients with good-risk clinical features did very well with sunitinib (Sutent) in the CheckMate-214 trial, so there may be some patients who could benefit from single-agent VEGF inhibitors, explains McDermott.